Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment patterns and outcomes of venetoclax and other agents post introduction of novel therapies in patients with chronic lymphocytic leukemia.

Next Previous
Trial Profile

Treatment patterns and outcomes of venetoclax and other agents post introduction of novel therapies in patients with chronic lymphocytic leukemia.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Acalabrutinib; Antineoplastics; Ibrutinib
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CORE

Most Recent Events

  • 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
  • 20 Mar 2020 Results (n=326) published in the Clinical Cancer Research.
  • 05 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top